ELI LILLY & Co
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly Zyprexa (olanzapine) by Quarter
Zyprexa (olanzapine) — Outside U.S. revenue ($M) [legacy] ($M)
Eli Lilly Zyprexa (olanzapine): $7.30M in Q4 2024, down 78.2% from a year earlier. That is the lowest of the 28 quarters on record here. No newer figure appears in the documents we track.
Where the Q4 2024 figure comes from
Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)
Source: Form 10-K (filed 2025-02-19) ↗
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Zyprexa (olanzapine) — Outside U.S. revenue ($M) [legacy] ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2024 | Dec 31, 2024 | 7.30 | -78.2% | Form 10-K (filed 2025-02-19) ↗ |
| Q3 2024 | Sep 30, 2024 | 29.8 | -97.9% | Form 10-Q (filed 2024-10-30) ↗ |
| Q4 2023 | Dec 31, 2023 | 33.5 | -52.8% | Form 10-K (filed 2025-02-19) ↗ |
| Q3 2023 | Sep 30, 2023 | 1,432 | +1,850.3% | Form 10-Q (filed 2024-10-30) ↗ |
| Q4 2022 | Dec 31, 2022 | 71 | -43.7% | Form 10-K (filed 2025-02-19) ↗ |
| Q3 2022 | Sep 30, 2022 | 73.4 | -17.2% | Form 10-Q (filed 2023-11-02) ↗ |
| Q2 2022 | Jun 30, 2022 | 78.6 | -9.6% | Form 10-Q (filed 2022-08-04) ↗ |
| Q1 2022 | Mar 31, 2022 | 83.5 | -6.1% | Form 10-Q (filed 2022-04-29) ↗ |
| Q4 2021 | Dec 31, 2021 | 126 | +33.8% | Form 10-K (filed 2024-02-21) ↗ |
| Q3 2021 | Sep 30, 2021 | 88.7 | -3.1% | Form 10-Q (filed 2022-11-01) ↗ |
| Q2 2021 | Jun 30, 2021 | 86.9 | -0.7% | Form 10-Q (filed 2022-08-04) ↗ |
| Q1 2021 | Mar 31, 2021 | 88.9 | +1.9% | Form 10-Q (filed 2022-04-29) ↗ |
| Q4 2020 | Dec 31, 2020 | 94.3 | +4.3% | Form 10-K (filed 2023-02-22) ↗ |
| Q3 2020 | Sep 30, 2020 | 91.5 | -2.9% | Form 10-Q (filed 2021-10-27) ↗ |
| Q2 2020 | Jun 30, 2020 | 87.5 | -8.0% | Form 10-Q (filed 2021-08-03) ↗ |
| Q1 2020 | Mar 31, 2020 | 87.2 | -10.9% | Form 10-Q (filed 2021-04-30) ↗ |
| Q4 2019 | Dec 31, 2019 | 90.4 | -11.6% | Form 10-K (filed 2022-02-23) ↗ |
| Q3 2019 | Sep 30, 2019 | 94.2 | -8.4% | Form 10-Q (filed 2020-10-28) ↗ |
| Q2 2019 | Jun 30, 2019 | 95.1 | -18.2% | Form 10-Q (filed 2020-07-31) ↗ |
| Q1 2019 | Mar 31, 2019 | 97.9 | -14.0% | Form 10-Q (filed 2020-05-01) ↗ |
| Q4 2018 | Dec 31, 2018 | 102 | -18.9% | Form 10-K (filed 2021-02-17) ↗ |
| Q3 2018 | Sep 30, 2018 | 103 | -19.7% | Form 10-Q (filed 2019-10-25) ↗ |
| Q2 2018 | Jun 30, 2018 | 116 | -9.1% | Form 10-Q (filed 2019-08-02) ↗ |
| Q1 2018 | Mar 31, 2018 | 114 | -8.1% | Form 10-Q (filed 2019-05-02) ↗ |
| Q4 2017 | Dec 31, 2017 | 126 | – | Form 10-K (filed 2020-02-19) ↗ |
| Q3 2017 | Sep 30, 2017 | 128 | – | Form 10-Q (filed 2018-11-06) ↗ |
| Q2 2017 | Jun 30, 2017 | 128 | – | Form 10-Q (filed 2018-07-25) ↗ |
| Q1 2017 | Mar 31, 2017 | 124 | – | Form 10-Q (filed 2018-04-27) ↗ |
Cite this data
StockData. (2026). Eli Lilly Zyprexa (olanzapine) ($M), quarterly Q1 2017–Q4 2024 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-zyprexa-nonus
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.